Literature DB >> 9755356

Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs.

C DeBattista1, M Sofuoglu, A F Schatzberg.   

Abstract

It has become common clinical practice to combine the selective serotonin reuptake inhibitors with other serotonergic agents for augmentation or adjunctive purposes. The empirical basis for using these combinations remains limited, but is growing. Also growing is a literature that suggests that even the most apparently benign combinations of serotonergic drugs carry at least some risk of serious pharmacokinetic or pharmacodynamic drug interactions, such as a serotonin syndrome.

Mesh:

Substances:

Year:  1998        PMID: 9755356     DOI: 10.1016/s0006-3223(98)00161-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

Review 1.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

2.  Use of trazodone to facilitate postsurgical confinement in dogs.

Authors:  Margaret E Gruen; Simon C Roe; Emily Griffith; Alexandra Hamilton; Barbara L Sherman
Journal:  J Am Vet Med Assoc       Date:  2014-08-01       Impact factor: 1.936

3.  Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?

Authors:  P McManus; A Mant; P Mitchell; D Birkett; J Dudley
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.